Search results

667 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter

Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

In development [GID-TA10577] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
PlGF-based testing to help diagnose suspected pre-eclampsia (Update of DG23)

In development [GID-DG10040] Expected publication date: 17 November 2021

Type

Diagnostics guidance

Status

In development
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

In development [GID-TA10759] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]

In development [GID-TA10588] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

In development [GID-TA10566] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]

In development [GID-TA10352] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

In development [GID-TA10222] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

In development [GID-TA10656] Expected publication date: 02 March 2022

Type

Technology appraisal guidance

Status

In development
SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea

In development [GID-DG10039] Expected publication date: 17 November 2021

Type

Diagnostics guidance

Status

In development
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

In development [GID-TA10591] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atherothrombotic events - vorapaxar [ID616]

In development [GID-TAG493] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Head and neck cancer - intensity modulated radiotherapy [ID15]

In development [GID-TAG397] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glaucoma - lerdelimumab (CAT-152) [ID383]

In development [GID-TAG381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]

In development [GID-TA10649] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

In development [GID-TA10416] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

In development [GID-TA10597] Expected publication date: 27 October 2021

Type

Technology appraisal guidance

Status

In development
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

In development [GID-TA10261] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

In development [GID-TA10087] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

In development [GID-TAG526] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development